Trial reportArchives of dermatological research2021
Botulinum toxin type A versus 5-Fluorouracil in treatment of keloid.
Trial report in Archives of dermatological research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 2 syntheses or guidelines pooled it, 35 citations in OpenAlex.
- Keloid treatments: an evidence-based systematic review of recent advances.Systematic reviews · 2023Pooled it
- Intralesional 5-Fluorouracil for Keloids: A Systematic Review.Journal of cutaneous medicine and surgeryPooled it
- Clinical observation on manual linear array technology (MLAT) with ultra-pulsed COLasers in medical science · 2025Trial
- Clinical Efficacy Analysis of Botulinum Toxin Type A Combined with Superficial Radiotherapy after Chest Keloid Surgery.Aesthetic plastic surgery · 2025Trial
- Comparing intralesional triamcinolone and verapamil-triamcinolone injections in keloids: A single-blinded randomised clinical trial.International wound journal · 2023Trial
- Comparative efficacy of intralesional therapies for keloid scars: a network meta-analysis.Annals of medicine · 2026Article
- An injectable photo-crosslinking silk hydrogel system with biphasic release of BTXA and 5-Fu promotes scarless wound healing.RSC advances · 2026Article
- Functional Compression Fabrics with Dual Scar-Suppressing and Antimicrobial Properties: Microencapsulation Design and Performance Evaluation.Journal of functional biomaterials · 2025Article
- Intralesional Botulinum Toxin A for Keloid Treatment: A Review of Efficacy, Safety, and Clinical Applications.Clinical, cosmetic and investigational dermatology · 2025Review
- Botulinum toxin on a mission to erase keloids: does the dream come true?Postepy dermatologii i alergologii · 2025Review
- Immediately Injections of Botulinum Toxin A After Surgical Excision for Ear Keloids: A Retrospective Study.The Journal of craniofacial surgery · 2024Article
- Pharmacotherapy for Keloids and Hypertrophic Scars.International journal of molecular sciences · 2024Review
- Hypertrophic Scars and Keloids: Advances in Treatment and Review of Established Therapies.American journal of clinical dermatology · 2023Review
- Comparing the Efficacy of Multiple Drugs Injection for the Treatment of Hypertrophic Scars and Keloid: A Network Meta-Analysis.Aesthetic plastic surgery · 2023Review
- Botulinum Toxin Type A Injection Improves the Intraperitoneal High Pressure in Rats Treated with Abdominal Wall Plasty.Computational intelligence and neuroscience · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Most therapeutic approaches for keloids remain clinically unsatisfactory. In the last years, intralesional botulinum toxin-A (IL BTX-A) was proposed for treatment of keloids. Our aim of the study was to compare the clinical efficacy of IL BTX-A and IL 5-Fluorouracil (IL 5-FU) in treatment of keloids. A total of 50 patients with keloids were included in the study, 22 patients (with 26 keloids) were treated with IL BTX-A monthly for up to 6 months and other 22 patients (with 27 keloids) were treated with IL 5-FU weekly for up to 6 weeks, while the remaining 6 patients, each having multiple keloids, were treated with both IL BTX-A for some lesions (8 keloids) and IL 5-FU for their remaining lesions (8 keloids). The clinical improvement was assessed according to flattening of the lesions. Side effects were recorded. A significantly better therapeutic response of keloids was detected after IL BTX-A than IL 5-FU (P = 0.041). IL BTX-A achieved excellent and good flattening of the lesions (58.8% and 20.6%) compared to (31.4% and 17.1%) after IL 5-FU, respectively. In BTX-A treated group, there was no statistically significant difference between the clinical response in small lesions compared to medium and large ones (P = 0.476). While in 5-FU treated group, small and medium lesions showed significantly better response than larger ones (P = 0.009). IL BTX-A caused fewer side effects than IL 5-FU, less pain, itching, no hyperpigmentation and less recurrence. Both IL BTX-A and IL 5-FU showed positive results in treatment of keloids. However, IL BTX-A showed higher clinical efficacy even in large size keloids with less side effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.